+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

The Harrington Prize for Innovation in Medicine

Harrington Discovery Institute

Important Dates

Call Opens for Nominations
April 6, 2026
Nomination Submission Deadline
September 14, 2026
Nominations Under Review
October - January
Announce 2027 Harrington Prize Recipient
March 2027

The Harrington Prize for Innovation in Medicine, presented by the American Society for Clinical Investigation and Harrington Discovery Institute, honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application. Each year one Harrington Prize recipient is chosen. The prize includes:

An unrestricted $20,000 honorarium
The Harrington Prize Lecture, delivered at the AAP-ASCI-APSA Joint Meeting
Participation in the Harrington Discovery Institute Scientific Symposium
A personal essay, published in the Journal of Clinical Investigation

AI Based Application Success Predictor

1. Strong translational therapeutic focus

The most competitive applications directly address:

therapeutic development,
drug discovery,
biologics,
gene therapies,
precision medicine,
rare disease therapeutics,
translational oncology,
neurodegeneration,
regenerative medicine.

Harrington programs specifically seek discoveries that can move from academia into clinical practice.

2. Clear pathway toward clinical application

One of the strongest predictors of success is:

realistic therapeutic development plans,
translational feasibility,
clinically actionable targets,
drug-development readiness,
commercialization potential.

The institute explicitly prioritizes projects capable of advancing toward patients and clinical translation.

3. Novel, validated biological targets

Competitive proposals commonly feature:

novel therapeutic targets,
strong mechanistic rationale,
validated disease biology,
differentiated therapeutic approaches,
high unmet medical need.

The Oxford-Harrington programs specifically highlight “novel, validated targets” as a key review priority.

4. Strong preliminary and proof-of-concept data

Successful applications usually include:

pilot efficacy data,
translational feasibility studies,
biomarker validation,
preclinical therapeutic evidence,
disease-model validation.

Because Harrington programs are highly translational, robust feasibility evidence substantially improves competitiveness.

5. Innovation and high-risk/high-reward science

Highly competitive projects often involve:

first-in-class therapeutics,
cell and gene therapies,
RNA therapeutics,
precision medicine,
AI-assisted drug discovery,
novel biologics,
advanced translational platforms.

Harrington explicitly encourages breakthrough innovation with major clinical potential.

6. Strong commercialization and IP potential

A distinctive Harrington-specific predictor is:

strong intellectual property strategy,
patent positioning,
commercial scalability,
industry partnership potential.

The Oxford-Harrington award guidance explicitly references commercialization potential and IP strength as important evaluation criteria.

7. Strong multidisciplinary translational team

High-scoring projects frequently involve:

physician-scientists,
translational biologists,
medicinal chemists,
bioengineers,
clinical investigators,
regulatory experts,
industry collaborators.

Collaborative translational ecosystems are highly valued.

8. Access to drug-development infrastructure

Competitive applicants often demonstrate access to:

GMP facilities,
medicinal chemistry,
translational core facilities,
animal models,
clinical trial infrastructure,
bioinformatics platforms.

Harrington programs specifically provide therapeutic-development support and infrastructure access.

9. Strong investigator track record

Important predictors include:

impactful publications,
prior translational achievements,
therapeutic-development experience,
prior grant success,
evidence of independent innovation leadership.

Physician-scientist leadership is particularly valued across Harrington programs.

10. Potential for scalable future investment

Reviewers strongly favor projects likely to:

attract venture or pharma partnerships,
generate NIH/foundation funding,
progress toward IND-enabling studies,
enter clinical trials,
create startup or licensing opportunities.

Harrington programs can provide additional acceleration funding and investment support for highly promising projects.

Common Reasons for Rejection

Frequent reviewer concerns include:

weak translational pathway,
insufficient therapeutic differentiation,
inadequate proof-of-concept data,
poor commercialization strategy,
weak IP positioning,
unrealistic development timelines,
insufficient clinical relevance,
lack of feasibility evidence.

Specialties

Others

Eligibility Requirements

MD or MD/PhD (or equivalent)
Does not need to be an ASCI member
No age or citizenship requirement
Self-nomination is not permitted
Must be available to deliver a lecture at the AAP-ASCI-APSA Joint Meeting
Must be available to participate in Harrington Discovery Institute Scientific Symposium
Must submit a personal essay for publication in the Journal of Clinical Investigation

Sponsor Details

Sponsor Institute/Organizations: Harrington Discovery Institute

Sponsor Type: Corporate/Non-Profit

Address: 11407 Euclid Ave, Floor 2, Cleveland, OH 44106

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity